Type of pegylated interferon matters: another milestone in the treatment of hepatitis C virus infection
- PMID: 22308133
- PMCID: PMC3269078
Type of pegylated interferon matters: another milestone in the treatment of hepatitis C virus infection
Similar articles
-
Cost Effectiveness of Daclatasvir Plus Asunaprevir Therapy for Chinese Patients with Chronic Hepatitis C Virus Genotype 1b.Clin Drug Investig. 2018 May;38(5):427-437. doi: 10.1007/s40261-018-0621-9. Clin Drug Investig. 2018. PMID: 29417464
-
Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial.Lancet Gastroenterol Hepatol. 2017 Dec;2(12):877-889. doi: 10.1016/S2468-1253(17)30288-1. Epub 2017 Sep 28. Lancet Gastroenterol Hepatol. 2017. PMID: 28964701 Clinical Trial.
-
Original Research: Analysis of hepatic microRNA alterations in response to hepatitis B virus infection and pegylated interferon alpha-2a treatment.Exp Biol Med (Maywood). 2016 Oct;241(16):1803-10. doi: 10.1177/1535370216647184. Epub 2016 May 4. Exp Biol Med (Maywood). 2016. PMID: 27190255 Free PMC article.
-
Update on viral hepatitis in 2004.Curr Opin Gastroenterol. 2005 May;21(3):300-7. doi: 10.1097/01.mog.0000158109.13722.36. Curr Opin Gastroenterol. 2005. PMID: 15818150 Review.
-
[Nontraumatic causes of bilateral avascular necrosis of the femoral head: link between hepatitis C and pegylated interferon].Acta Ortop Mex. 2015 May-Jun;29(3):172-5. Acta Ortop Mex. 2015. PMID: 26999969 Review. Spanish.
Cited by
-
Peginterferon alfa-2a is associated with elevations in alanine aminotransferase at the end of treatment in chronic hepatitis C patients with sustained virologic response.PLoS One. 2014 Jun 17;9(6):e100207. doi: 10.1371/journal.pone.0100207. eCollection 2014. PLoS One. 2014. PMID: 24937007 Free PMC article.
References
-
- World Health Organization. Hepatitis C. [database on the Internet] 2004 [cited 2009]. Available from: http://www. who.int/mediacentre/factsheets/fs164/en/index.html.
-
- Alter H. Viral hepatitis. Hepatology. 2006;43(2 Suppl 1):S230–4. - PubMed
-
- Foster G, Mathurin P. Hepatitis C virus therapy to date. Antivir Ther. 2008;13 Suppl 1:3–8. - PubMed
-
- Harris JM, Martin NE, Modi M. Pegylation: a novel process for modifying pharmacokinetics. Clin Pharmacokinet. 2001;40(7):539–51. Available from http://dx.doi.org/10.2165/00003088-200140070-00005. - DOI - PubMed
-
- Foster GR. Review article: pegylated interferons: chemical and clinical differences. Aliment Pharmacol Ther. 2004;20(8):825–30. - PubMed
LinkOut - more resources
Full Text Sources